World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01390961
Date of registration: 07/07/2011
Primary sponsor: Hom, Milton M., OD, FAAO
Public title: Comparison of Tolerability Between Two Allergy Drops
Scientific title: Comparison of Tolerability Between Two Allergy Drops
Date of first enrolment: August 2011
Target sample size: 48
Recruitment status: Enrolling by invitation
URL:  http://clinicaltrials.gov/show/NCT01390961
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment  
Countries of recruitment
United States
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

- Between the ages of 18 and over inclusive.

- Males or females

- Patient is in generally good & stable overall health.

- Patient likely to comply with study guidelines & study visits.

- Informed consent signed.

- History of allergic conjunctivitis

- Current symptoms of allergic conjunctivitis assessed by the investigator

Exclusion Criteria:

- Corneal refractive surgery or contact lens wear within 6 months of this study.

- Current use of Restasis

- Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.

- Pregnant or lactating women.

- Ocular pathology (includes glaucoma and cataract), which could impact results and/or
place patient at risk.



Age minimum: 18 Months
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Allergic Conjunctivitis
Intervention(s)
Drug: alacaftadine and naphazoline HCl & pheniramine maleate
Primary Outcome(s)
Tolerability [Time Frame: 8 weeks]
Secondary Outcome(s)
Secondary ID(s)
IIT-000256
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Allergan
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history